A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
| Τίτλος: | A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab. |
|---|---|
| Συγγραφείς: | Hoimes CJ; Duke Cancer Institute; Duke University, Durham, NC, USA., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO, USA., Milowsky MI; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA, USA., Bilen MA; Winship Cancer Institute of Emory University, Hematology & Medical Oncology, Atlanta, GA, USA., Gupta S; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Srinivas S; Stanford University Medical Center, Stanford, CA, USA., Merchan JR; University of Miami, Medical Oncology, Miami, FL, USA., McKay RR; University of California San Diego Moores Cancer Center, San Diego, CA, USA., Petrylak DP; Yale Comprehensive Cancer Center, New Haven, CT, USA., Sasse C; Astellas Pharma Global Development, Northbrook, IL, USA., Moreno BH; Merck & Co., Inc., Rahway, NJ, USA., Yu Y; Seagen Inc., Bothell, WA, USA., Carret AS; Seagen Inc., Bothell, WA, USA., Rosenberg JE; Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY, USA. |
| Πηγή: | Future oncology (London, England) [Future Oncol] 2024 Mar; Vol. 20 (7), pp. 351-360. Date of Electronic Publication: 2023 Nov 23. |
| Τύπος έκδοσης: | Patient Education Handout |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2024- : [Milton Park, Oxfordshire] : Taylor & Francis Original Publication: London : Future Medicine Ltd., c2005- |
| Ιατρικοί όροι (MeSH): | Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology , Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology, Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Humans |
| Περίληψη: | What Is This Summary About?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder. What Were the Results?: In the 45 patients studied, around 16% did have serious side effects, but most side effects were manageable. Twenty-four percent of patients, however, stopped the study treatment because of their side effects. Within about 2 months of starting treatment, most patients' (73%) tumors were smaller and stayed smaller, on average, for more than 2 years. What Do the Results Mean?: The combination of enfortumab vedotin plus pembrolizumab is a new treatment option for patients with locally advanced or metastatic urothelial cancer when they cannot receive the typical treatment, cisplatin. Advanced or metastatic urothelial cancer is a type of cancer where the cancer has already spread outside of the bladder or urinary tract. |
| Grant Information: | P30 CA008748 United States CA NCI NIH HHS |
| Contributed Indexing: | Keywords: enfortumab vedotin; lay summary; pembrolizumab; plain language summary; urothelial cancer |
| Substance Nomenclature: | 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) DLE8519RWM (enfortumab vedotin) DPT0O3T46P (pembrolizumab) |
| Entry Date(s): | Date Created: 20231123 Date Completed: 20240315 Latest Revision: 20260305 |
| Update Code: | 20260305 |
| PubMed Central ID: | PMC10988537 |
| DOI: | 10.2217/fon-2023-0112 |
| PMID: | 37994649 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1744-8301 |
|---|---|
| DOI: | 10.2217/fon-2023-0112 |